<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00220727</url>
  </required_header>
  <id_info>
    <org_study_id>100422</org_study_id>
    <nct_id>NCT00220727</nct_id>
  </id_info>
  <brief_title>Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP</brief_title>
  <official_title>Randomized, Controlled, Open Study Investigating IGIV-C, 10% Given at Different Infusion Rates on Intravascular Hemolysis in Patients With Idiopathic (Immune) Thrombocytopenic Purpura (ITP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grifols Therapeutics LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grifols Therapeutics LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine if the safety and tolerability of Immune Globulin
      Intravenous (Human), 10% Caprylate/Chromatograph Purified (IGIV-C) is similar when infused at
      two different infusion rates.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized, single-center, open, cross-over trial in patients with a
      confirmed diagnosis of Idiopathic Thrombocytopenia Purpura (ITP). ITP is defined as isolated
      thrombocytopenia in a patient with no other clinically apparent associated conditions or
      factors that are known to cause thrombocytopenia as defined by the ITP Practice Guidelines
      Committee of the American Society of Hematology.

      Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified (IGIV-C) at a dose
      of 1.0 g/kg will be given on 2 occasions as a single daily infusion for platelet counts &lt;
      30,000 microliters (uL) or if clinically indicated, at maximum intervals of six weeks.
      Eligible patients will be randomized into one of two cross-over groups. Patients randomized
      to Group 1 will receive their first IGIV-C infusion at a rate of 0.08 mL/kg/min and their
      second infusion at a rate of 0.14 mL/kg/min. Conversely patients randomized to Group 2 will
      receive their first IGIV-C infusion at a rate of 0.14 mL/kg/min and their second infusion at
      a rate of 0.08 mL/kg/min according to the following schema:

      Group 1:

        -  Infusion #1 (Week 0) IGIV-C (0.08 mL/kg/min)

        -  Infusion #2 (Week &lt;6) IGIV-C (0.14 mL/kg/min)

      Group 2:

        -  Infusion #1 (Week 0) IGIV-C (0.14 mL/kg/min)

        -  Infusion #2 (Week &lt;6) IGIV-C (0.08 mL/kg/min)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">October 2003</completion_date>
  <primary_completion_date type="Actual">October 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Free Hemoglobin</measure>
    <time_frame>24 hours after treatment</time_frame>
    <description>Free hemoglobin as a measure to assess hemolysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hematocrit</measure>
    <time_frame>24 hrs after treatment</time_frame>
    <description>Hematocrit as a measure to assess hemolysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Red Blood Cells</measure>
    <time_frame>24 hrs after treatment</time_frame>
    <description>Red blood cells as a measure to assess hemolysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Platelet Levels</measure>
    <time_frame>24 hours Post infusion and Day 7</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Infusion Related Adverse Events</measure>
    <time_frame>48 hours after treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Purpura, Thrombocytopenic, Idiopathic</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infusion #1 (Week 0) IGIV-C (0.08 mL/kg/min); Infusion #2 (Week &lt;6) IGIV-C (0.14 mL/kg/min)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infusion #1 (Week 0) IGIV-C (0.14 mL/kg/min); Infusion #2 (Week &lt;6) IGIV-C (0.08 mL/kg/min)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified</intervention_name>
    <description>IGIV-C 10% at a dose of 1.0g/kg was to be given on 2 occasions as a single daily infusion: Group 1 were to receive their first IGIV-C, 10-% infusion at a rate of 0.08 mL/kg/min and a second infusion at 0.14 mL/kg/min. and Group 2 were to receive their first IGIV-C, 10-% infusion at a rate of 0.14 mL/kg/min and a second infusion at a rate of 0.08 mL/kg/min.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Gamunex®</other_name>
    <other_name>IGIVnex®</other_name>
    <other_name>Gaminex</other_name>
    <other_name>IGIV-C</other_name>
    <other_name>IGIV-C, 10%</other_name>
    <other_name>IVIG</other_name>
    <other_name>BAY 41-1000</other_name>
    <other_name>TAL-05-00004</other_name>
    <other_name>Immune Globulin (Human), 10% (IGIV)</other_name>
    <other_name>Immune Globulin Intravenous, 10% by Chromatography Process</other_name>
    <other_name>NDC 13533-645-12</other_name>
    <other_name>NDC 13533-645-15</other_name>
    <other_name>NDC 13533-645-20</other_name>
    <other_name>NDC 13533-645-24</other_name>
    <other_name>NDC 13533-645-71</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent from patient or legal guardian (according to institutional
             review board requirements)obtained prior to initiation of any study related procedures

          -  Male and female subjects age between 12 and 75 years

          -  Confirmed diagnosis of ITP logged in medical records available prior to entry into the
             trial.

          -  Patients must have a platelet count &lt; 30 x Giga/L (this level can be higher if
             clinically indicated).

          -  Previously splenectomized patients may be included.

          -  Any previously conducted bone marrow aspirations if conducted following diagnosis of
             ITP must be consistent with the ITP diagnosis (increased or normal levels of
             megakaryocytes in otherwise normal bone marrow).

        Exclusion Criteria:

          -  History of allergic or other clinically significant reaction to human gamma globulin
             or other plasma proteins and/or blood products.

          -  Female patient who is pregnant or lactating or is not on an adequate program of
             contraception if of child-bearing potential.

          -  Documented history of selective immunoglobulin A (IgA) deficiency (serum &lt;5.0 mg/dL)
             and known antibodies to IgA.

          -  Currently on intermittent prednisone therapy. Prednisone therapy is allowed only if
             the patient has been on stable daily doses of prednisone for the preceding month and
             maintains the same treatment regimen throughout the study.

          -  Renal or liver impairment defined by creatinine &gt; 2.5 mg/dL, or direct bilirubin &gt;1.5
             X the upper limit of normal or liver transaminases (AST or ALT) &gt; 3 times the upper
             limit of normal.

          -  Received anti-D or IGIV infusions within the past 14 days

          -  Pre-treatment with the exception of acetominophen, routinely required to
             control/ameliorate IGIV infusion-related adverse events (AEs), or any patient who has
             been, unresponsive to IGIV therapy for their ITP

          -  History or clinical evidence of medical conditions felt to be the underlying cause of
             their thrombocytopenia. Such conditions commonly include systemic lupus erythematosus,
             history of chronic lymphocytic leukemia, dysplasia, agammaglobulinemia, treatment with
             heparin, quinidine, quinine, trimethoprim-sulfamethoxazole, or ticlopidine or any
             other drug thought to be the cause of patient's thrombocytopenia, congenital or
             hereditary thrombocytopenia, or pseudothrombocytopenia (clumping on peripheral blood
             smear)

          -  Conditions that could alter protein catabolism and/or immunoglobulin G (IgG)
             utilization (e.g. protein-losing enteropathies, nephrotic syndrome)

          -  Congestive heart failure (New York Heart Association Stage III or IV)

          -  Diabetes mellitus

          -  Paraproteinemia

          -  Concomitant nephrotoxic drugs

          -  Hemoglobin level more than 2g/L below the lower limit of normal.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Bussel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York Presbyterian Hospital-Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021-4885</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/ucm089390.htm</url>
    <description>FDA Product Approval - Gamunex®</description>
  </link>
  <reference>
    <citation>Bussel JB, Hanna K; IGIV-C in ITP Study Group. Safety and tolerability of a novel chromatography-based intravenous immunoglobulin when administered at a high infusion rate in patients with immune thrombocytopenic purpura. Am J Hematol. 2007 Mar;82(3):192-8.</citation>
    <PMID>17109385</PMID>
  </reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <results_first_submitted>September 24, 2009</results_first_submitted>
  <results_first_submitted_qc>August 19, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 20, 2014</results_first_posted>
  <last_update_submitted>March 28, 2016</last_update_submitted>
  <last_update_submitted_qc>March 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Idiopathic (Immune) Thrombocytopenic Purpura</keyword>
  <keyword>Immunoglobulin G</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Purpura</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Single-center, open label study in patients with a confirmed diagnosis of Idiopathic Thrombocytopenic Purpura (ITP).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>IGIV-C, 10% - 0.08/0.14 mL/kg/Min</title>
          <description>Infusion #1 (Week 0 IGIV-C (0.08 mL/kg/min); Infusion #2 (Week &lt;6) IGIV-C (0.14 mL/kg/min)</description>
        </group>
        <group group_id="P2">
          <title>IGIV-C, 10% - 0.14/0.08 mL/kg/Min</title>
          <description>Infusion #1 (Week 0) IGIV-C (0.14 mL/kg/min); Infusion #2 (Week &lt;6) IGIV-C (0.08 mL/kg/min)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Infusion (Week 0)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Infusion (Week &lt;6)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Pt did not meet study requirement</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>IGIV-C, 10% - 0.08/0.14 mL/kg/Min</title>
          <description>Infusion #1 (Week 0 IGIV-C (0.08 mL/kg/min); Infusion #2 (Week &lt;6) IGIV-C (0.14 mL/kg/min)</description>
        </group>
        <group group_id="B2">
          <title>IGIV-C, 10% - 0.14/0.08 mL/kg/Min</title>
          <description>Infusion #1 (Week 0) IGIV-C (0.14 mL/kg/min); Infusion #2 (Week &lt;6) IGIV-C (0.08 mL/kg/min)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.75" spread="15.78"/>
                    <measurement group_id="B2" value="47.50" spread="14.89"/>
                    <measurement group_id="B3" value="47.63" spread="14.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Free Hemoglobin</title>
        <description>Free hemoglobin as a measure to assess hemolysis.</description>
        <time_frame>24 hours after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IGIV-C, 10% (0.08 mL/kg/Min)</title>
            <description>Infusion #1 (Week 0 IGIV-C (0.08 mL/kg/min); Infusion #2 (Week &lt;6) IGIV-C (0.14 mL/kg/min)</description>
          </group>
          <group group_id="O2">
            <title>IGIV-C, 10% (0.14 mL/kg/Min)</title>
            <description>Infusion #1 (Week 0) IGIV-C (0.14 mL/kg/min); Infusion #2 (Week &lt;6) IGIV-C (0.08 mL/kg/min)</description>
          </group>
        </group_list>
        <measure>
          <title>Free Hemoglobin</title>
          <description>Free hemoglobin as a measure to assess hemolysis.</description>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.057" spread="1.778"/>
                    <measurement group_id="O2" value="12.371" spread="2.644"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Infusion Related Adverse Events</title>
        <time_frame>48 hours after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IGIV-C, 10% (0.08 mL/kg/Min)</title>
            <description>Slow Infusion Rate IGIV-C (0.08 mL/kg/min);</description>
          </group>
          <group group_id="O2">
            <title>IGIV-C, 10% (0.14 mL/kg/Min)</title>
            <description>Rapid Infusion Rate IGIV-C (0.14 mL/kg/min);</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Infusion Related Adverse Events</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hematocrit</title>
        <description>Hematocrit as a measure to assess hemolysis</description>
        <time_frame>24 hrs after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IGIV-C, 10% (0.08 mL/kg/Min)</title>
            <description>Slow Infusion Rate IGIV-C (0.08 mL/kg/min);</description>
          </group>
          <group group_id="O2">
            <title>IGIV-C, 10% (0.14 mL/kg/Min)</title>
            <description>Rapid Infusion Rate IGIV-C (0.14 mL/kg/min);</description>
          </group>
        </group_list>
        <measure>
          <title>Hematocrit</title>
          <description>Hematocrit as a measure to assess hemolysis</description>
          <units>percentage of blood</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.80" spread="4.711"/>
                    <measurement group_id="O2" value="35.043" spread="6.793"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Red Blood Cells</title>
        <description>Red blood cells as a measure to assess hemolysis</description>
        <time_frame>24 hrs after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IGIV-C, 10% (0.08 mL/kg/Min)</title>
            <description>Slow Infusion Rate IGIV-C (0.08 mL/kg/min);</description>
          </group>
          <group group_id="O2">
            <title>IGIV-C, 10% (0.14 mL/kg/Min)</title>
            <description>Rapid Infusion Rate IGIV-C (0.14 mL/kg/min);</description>
          </group>
        </group_list>
        <measure>
          <title>Red Blood Cells</title>
          <description>Red blood cells as a measure to assess hemolysis</description>
          <units>10^12 cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1514" spread=".4820"/>
                    <measurement group_id="O2" value="4.0786" spread="0.8258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Platelet Levels</title>
        <time_frame>24 hours Post infusion and Day 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IGIV-C, 10% (0.08 mL/kg/Min)</title>
            <description>Slow Infusion Rate IGIV-C (0.08 mL/kg/min);</description>
          </group>
          <group group_id="O2">
            <title>IGIV-C, 10% (0.14 mL/kg/Min)</title>
            <description>Rapid Infusion Rate IGIV-C (0.14 mL/kg/min);</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Platelet Levels</title>
          <units>Giga/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.50" spread="28.47"/>
                    <measurement group_id="O2" value="6.86" spread="3.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours post infusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.17" spread="35.49"/>
                    <measurement group_id="O2" value="42.29" spread="12.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76" spread="138.35"/>
                    <measurement group_id="O2" value="118.7" spread="165.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>IGIV-C, 10% - 0.08 mL/kg/Min</title>
          <description>IGIV-C (0.08 mL/kg/min);</description>
        </group>
        <group group_id="E2">
          <title>IGIV-C, 10% - 0.14 mL/kg/Min</title>
          <description>IGIV-C (0.14 mL/kg/min);</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Distention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The investigator will be free to disclose at scientific meetings and to publish in the scientific literature data resulting from these trials. A copy of any manuscript must be sent to sponsor for review at least 1 month prior to submission for publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Henry Li</name_or_title>
      <organization>Grifols Therapeutics</organization>
      <phone>1-800-520-2807</phone>
      <email>henry.li@grifols.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

